Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Opinion
Video
Transforming Breast Cancer Treatment Through ADC-Targeting Mechanisms
Panelists discuss how antibody-drug conjugates (ADCs) combine monoclonal antibodies with cytotoxic payloads, enabling precise targeting of breast cancer (BC) cells through specific antigen recognition. Upon binding, the ADC-antigen complex is internalized, releasing the toxic payload inside cancer cells while largely sparing healthy tissue. This targeted approach offers improved efficacy and reduces systemic toxicity compared with traditional chemotherapy's broad cytotoxic effects.
Video content above has been prompted by the following:
- Can you explain how the mechanism of ADCs translates into effective targeting of BC cells, and how this compares with traditional therapies?
Related Videos
Related Content
